Skip to main content

Table 3 Contrast-enhanced MRI findings according to response at each time point

From: Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models

Variable

Patients with pCR

Patients with non-pCR

P value

AUC

95% CI

P value

Pre-treatment

 No. of patients

54

90

    

 Size (mm)

39.8 ± 21.2

44.3 ± 18.8

0.189

0.578

0.475, 0.681

0.119

 RER (%)

164.1 ± 66.5

152.6 ± 57.0

0.271

0.551

0.452, 0.650

0.305

Mid-treatment

 No. of patients

37

64

    

 ΔSize (mm)

− 27.4 ± 16.6

− 17.1 ± 14.2

0.001

0.698

0.591, 0.804

0.001

 ΔRER (%)

− 101.2 ± 81.1

− 36.8 ± 81.1

 < 0.001

0.706

0.603, 0.809

0.001

Post-treatment

 No. of patients

33

65

    

 ΔSize (mm)

− 34.0 ± 18.9

− 24.6 ± 18.5

0.021

0.661

0.549, 0.774

0.009

 ΔRER (%)

− 135.1 ± 81.4

− 60.5 ± 79.8

 < 0.001

0.734

0.633, 0.836

 < 0.001

  1. *P < 0.0083 (0.05/6) is defined as the Bonferroni-corrected significance level
  2. RER: relative enhancement ratio; pCR: pathologic complete response; AUC: area under the receiver operating characteristic curve; CI confidence interval